Broadly Neutralizing Antibodies Delayed Rebound in HIV Patients Who Stopped ART
(MedPage Today) — SAN FRANCISCO — Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral therapy (ART) avoided rebound for 5 months, a randomized trial showed.
At 20 weeks from analytical…
